We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
76
Cullinan Oncology
CGEM
$1.4B
$29.5M 0.3%
1,146,145
– –
SCPH
77
DELISTED
scPharmaceuticals
SCPH
$29.3M 0.3%
4,797,148
– –
KALA icon
78
KALA BIO
KALA
$13.3M
$29M 0.29%
2,188
– –
SRRA
79
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$28.8M 0.29%
1,477,320
– –
LAB icon
80
Standard BioTools
LAB
$252M
$28.7M 0.29%
4,661,871
+62,300
+1% +$333K
ARCT icon
81
Arcturus Therapeutics
ARCT
$432M
$28.7M 0.29%
848,503
-358,383
-30% -$12.1M
CRIS icon
82
Curis
CRIS
$3.61M
$28.4M 0.29%
8,804
-2,112
-19% -$9.54M
SYRE icon
83
Spyre Therapeutics
SYRE
$7.97B
$27.9M 0.28%
160,621
– –
ALXN
84
DELISTED
Alexion Pharmaceuticals
ALXN
$27.7M 0.28%
150,900
+48,800
+48% +$8.38M
ALPN
85
DELISTED
Alpine Immune Sciences Inc
ALPN
$27.6M 0.28%
3,070,955
– –
APTO
86
DELISTED
Aptose Biosciences, Inc.
APTO
$26.7M 0.27%
17,844
– –
FUSN
87
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$26.1M 0.26%
3,224,770
– –
XENE icon
88
Xenon Pharmaceuticals
XENE
$5.81B
$24.8M 0.25%
1,334,217
-1,163,700
-47% -$21.5M
BIIB icon
89
Biogen
BIIB
$32.3B
$23.3M 0.24%
67,400
-14,600
-18% -$4.42M
FLXN
90
DELISTED
Flexion Therapeutics, Inc.
FLXN
$22.8M 0.23%
2,769,383
+461,300
+20% +$3.92M
CALC icon
91
CalciMedica
CALC
$3.17M
$22.6M 0.23%
297,382
– –
OLMA icon
92
Olema Pharmaceuticals
OLMA
$899M
$22.6M 0.23%
807,792
+151,666
+23% +$4.32M
NXTC icon
93
NextCure
NXTC
$27.9M
$21.8M 0.22%
225,918
– –
CRVS icon
94
Corvus Pharmaceuticals
CRVS
$1.19B
$21.5M 0.22%
8,053,298
– –
ELVN icon
95
Enliven Therapeutics
ELVN
$4.24B
$21.5M 0.22%
679,976
– –
PCVX icon
96
Vaxcyte
PCVX
$8.9B
$21.3M 0.22%
945,400
+296,626
+46% +$6.07M
DMRA
97
Damora Therapeutics
DMRA
$1.79B
$20.7M 0.21%
163,637
– –
DNTH icon
98
Dianthus Therapeutics
DNTH
$5.92B
$19.9M 0.2%
127,110
+67,794
+114% +$12.5M
GILD icon
99
Gilead Sciences
GILD
$181B
$19.8M 0.2%
287,600
– –
KDNY
100
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$18.8M 0.19%
1,333,801
+83,800
+7% +$1.34M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.